Clin2
NCT06366945Possibly a fitNot yet recruiting

Testing a drug combo before surgery for head and neck cancer

Head and Neck Squamous Cell CarcinomaHead and Neck CancerHNSCCHead Cancer Neck

Treatments studied

Part of Cancer clinical trials.

This trial tests a combination of three drugs (tirelizumab, carboplatin, and a special form of paclitaxel) given before surgery to treat advanced head and neck cancer. The goal is to see if this treatment can shrink the tumor and improve outcomes.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
85 people
Ages
18 years to 75 years
Study type
Interventional

Who can take part

  • You have head and neck cancer that has spread to lymph nodes but not elsewhere in the body.
  • You are able to perform daily activities without help (ECOG 0 or 1).
  • You have not had chemotherapy, immunotherapy, or radiation for this cancer before.
  • You do not have active autoimmune diseases (like lupus or rheumatoid arthritis) that require treatment.
  • You do not have uncontrolled heart problems, infections, or other serious health issues.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06016413Not yet recruiting· Phase 2
Immunotherapy and Chemotherapy Before Surgery for Head and Neck Cancer

This trial tests a new combination of an immunotherapy drug (adelbelimab) plus chemotherapy given before surgery for head and neck cancer. The goal is to see if this treatment can shrink tumors and improve outcomes for people with advanced but removable head and neck squamous cell carcinoma.

Guangzhou, Guangdong
NCT07393477Not yet recruiting· Phase 2
Study of a new drug combo for head and neck cancer before surgery

This trial tests a combination of three drugs (becotatug vedotin, pucotenlimab, and cisplatin) given before surgery for head and neck cancer that has not spread far. The goal is to see if this treatment shrinks tumors and improves outcomes for patients with stage 3 or 4A disease.

Hangzhou, Zhejiang
NCT07618624Enrolling by invitation· Phase 2
Drug combination before surgery for recurrent head and neck cancer

This trial tests three drugs (finotonlimab, cetuximab, and docetaxel) given before surgery to remove recurrent head and neck cancer in patients whose cancer stopped responding to previous immunotherapy. The goal is to shrink the tumor and improve surgical outcomes.

Foshan, Guangdong
NCT06323369Recruiting· Phase 2
Tislelizumab plus chemo before surgery vs surgery alone for head and neck cancer

This trial tests whether giving tislelizumab (an immunotherapy) with chemotherapy before surgery works better than surgery alone for people with head and neck cancer that has not spread to lymph nodes. It's for cancers that can be removed with surgery, and the goal is to see if the pre-surgery treatment improves outcomes.

Guangzhou, Yuexiu
NCT05993858Not yet recruiting· Phase 2
Immunotherapy and targeted therapy before head and neck cancer surgery

This trial tests a combination of two drugs—an immunotherapy (PD-1 inhibitor) and a targeted therapy (cetuximab)—given before surgery to shrink advanced head and neck cancers. The goal is to see if this approach can lower the risk of the cancer coming back.

Wuhan, Hebei
NCT07778732Not yet recruiting· Phase 2
Combination treatment before surgery for head and neck cancer

This trial tests a combination of three drugs—adebrelimab (an immunotherapy), dalpiciclib (a targeted therapy), and chemotherapy—given before surgery to shrink head and neck cancer tumors. The goal is to see if this treatment helps remove the cancer and improves outcomes.

Hear when a new Head and Neck Squamous Cell Carcinoma trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.